Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: A case report
Số trang: 4
Loại file: pdf
Dung lượng: 1.29 MB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC).
Nội dung trích xuất từ tài liệu:
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: A case report
Nội dung trích xuất từ tài liệu:
Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: A case report
Tìm kiếm theo từ khóa liên quan:
BMC Pulmonary Medicine Idiopathic pulmonary fibrosis Acute exacerbation Randomized phase 3 trials Pirfenidone therapyTài liệu có liên quan:
-
9 trang 31 0 0
-
Quality of life is associated with physical activity and fitness in cystic fibrosis
9 trang 30 0 0 -
Clinical impact of cardiovascular disease on patients with bronchiectasis
7 trang 30 0 0 -
7 trang 30 0 0
-
7 trang 30 0 0
-
11 trang 29 0 0
-
9 trang 29 0 0
-
Efect of periodontal therapy on COPD outcomes: A systematic review
16 trang 25 0 0 -
10 trang 25 0 0
-
9 trang 24 0 0